Core Viewpoint - Silver诺医药-B (02591) has seen a stock price increase of over 5%, marking three consecutive days of gains, currently trading at 43.42 HKD with a transaction volume of 7.6433 million HKD [1] Group 1: Stock Performance - The stock price of Silver诺医药-B has risen by 5.03% [1] - The current trading price is 43.42 HKD [1] - The trading volume reached 7.6433 million HKD [1] Group 2: Index Inclusion - Silver诺医药 has been included in the Hang Seng Composite Index, with changes effective from December 8, 2025 [1] - This inclusion is part of the quarterly review results of the Hang Seng Index series [1] Group 3: Company Overview - Silver诺医药 is focused on the field of metabolic diseases [1] - The company has multiple innovative drug development pipelines targeting diabetes, obesity, and non-alcoholic fatty liver disease, all of which are self-developed [1] - The company holds global intellectual property rights and has a comprehensive global research and market layout [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02591 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 420,285,370 | RMB | | 1 RMB | | 420,285,370 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 420,285,370 | RMB | | 1 RMB | | 420,285,370 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | ...

银诺医药-B(02591)公布，于2025年12月1日，公司及银诺技术(公司一间直接全资附属公司)以代价合共 人民币1.25亿元(即其总本金额)分别向宁波银行认购一款结构性存款产品(即宁波银行结构性存款产 品)。 ...

Core Viewpoint - Silver诺医药-B (02591.HK) announced the subscription of a structured deposit product from Ningbo Bank for a total consideration of RMB 125 million, which represents the total principal amount [1] Group 1 - The company, along with its wholly-owned subsidiary Silver诺技术, will subscribe to the structured deposit product [1] - The total investment amount for the structured deposit product is RMB 125 million [1]

Core Viewpoint - Silver诺医药-B (02591) announced that on December 1, 2025, the company and its wholly-owned subsidiary, Silver诺技术, will subscribe to a structured deposit product from Ningbo Bank for a total consideration of RMB 125 million, which is equivalent to its total principal amount [1] Group 1 - The total investment amount for the structured deposit product is RMB 125 million [1] - The investment will be made by both Silver诺医药-B and its subsidiary Silver诺技术 [1] - The subscription is set to take place on December 1, 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Guangzhou Innogen Pharmaceutical Group Co., Ltd. 廣州銀諾醫藥集團股份有限公司 （於中華人民共和國成立的股份有限公司） （股份代號：2591） 有關認購結構性存款產品的須予披露交易 董事會宣佈，於2025年12月1日，本公司及銀諾技術（本公司一間直接全資附屬公 司）以代價合共人民幣125,000,000元（即其總本金額）分別向寧波銀行認購一款結 構性存款產品（即寧波銀行結構性存款產品）。 本公司及銀諾技術各自認購寧波銀行結構性存款產品的主要條款載列如下： | 認購方 | 產品名稱 | 本金額 | 認購日期 | 生效日期 | 到期日 | 預期年化回報率 | | --- | --- | --- | --- | --- | --- | --- | | 本公司 | 寧波銀行結構性 | 人民幣 | 2025年12月1日 | 2025年12月3日 | 2025年12月3 ...

Group 1 - Silver诺医药-B (02591.HK) shares increased nearly 7% in a single trading day [2] - Over the past four trading days, the stock price has surged over 50% [2] - As of the latest update, the stock is trading at 44.68 HKD with a transaction volume of 35.366 million HKD [2]

Group 1 - The core viewpoint of the article highlights that Sino Biopharmaceutical-B (02591) has seen a significant stock price increase of over 50% in four trading days, with a current price of 44.68 HKD and a trading volume of 35.37 million HKD [1] - On November 21, the results of the Hang Seng Index series quarterly review were released, and Sino Biopharmaceutical was included in the Hang Seng Composite Index, with the change effective from December 8, 2025 [1] - According to CICC's forecast, Sino Biopharmaceutical is expected to meet the criteria for inclusion in the Hong Kong Stock Connect [1] Group 2 - Sino Biopharmaceutical is focused on the field of metabolic diseases and has a pipeline of innovative drugs targeting conditions such as diabetes, obesity, and non-alcoholic fatty liver disease, all of which are self-developed and possess global intellectual property rights [1] - The company has a comprehensive global research and market layout [1]

Core Viewpoint - Silver诺医药-B (02591) has seen a significant stock price increase, with a rise of over 30% recently, and currently up 6.11% to 40.3 HKD, with a trading volume of 23.13 million HKD [1] Group 1: Stock Performance - The stock price of Silver诺医药-B increased by over 30% yesterday [1] - As of the latest update, the stock is trading at 40.3 HKD, reflecting a 6.11% increase [1] - The trading volume reached 23.13 million HKD [1] Group 2: Market Inclusion - On November 21, the results of the Hang Seng Index series quarterly review were announced, with Silver诺医药 being included in the Hang Seng Composite Index [1] - The changes from this review will take effect on December 8, 2025 [1] Group 3: Product and Research Insights - According to a report from Shanghai Securities, Silver诺医药's Supraglutide α demonstrates good safety and efficacy in lowering blood sugar and weight [1] - The company shows significant advantages in treating chronic metabolic diseases such as diabetes, obesity, and fatty liver [1] - The listing on the Hong Kong Stock Exchange is expected to facilitate the advancement of the company's research pipeline and commercialization efforts [1]

每经AI快讯，银诺医药-B(02591.HK)涨超6%，昨日股价飙涨超30%。截至发稿，涨6.11%，报40.3港 元，成交额2313.13万港元。 ...